Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era

Alexandra Wilson; Kimberly Altman; Terri Schindler; Sarah Jane Schwarzenberg

doi:10.1016/j.ccm.2022.06.012

Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era

Alexandra Wilson
, Kimberly Altman
, Terri Schindler
, Sarah Jane Schwarzenberg

Pediatric Gastroenterology, Hepatology & Nutrition

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Attainment and maintenance of good nutrition has been an important aspect of management in cystic fibrosis (CF) for decades. In the era of highly effective modulator therapy for CF, the quality of the nutrients we recommend is increasingly important. Our therapy must support our patients' health for many years beyond what we previously thought. Preventing cardiovascular disease, reducing hyperlipidemia, and optimizing lean body mass for active, longer lives now join the long-standing goal of promoting lung function through nutrition. This chapter summarizes recent developments in nutrition in people with CF, with an eye to the evolution of our practice.

Original language	English (US)
Pages (from-to)	727-742
Number of pages	16
Journal	Clinics in Chest Medicine
Volume	43
Issue number	4
DOIs	https://doi.org/10.1016/j.ccm.2022.06.012
State	Published - Dec 2022

Bibliographical note

Funding Information:
S.J. Schwarzenberg is a consultant for Abbvie, Mirium, Nestle, and UpToDate and has grant funding from the Cystic Fibrosis Foundation , the National Institutes of Health , and Gilead . T. Schindler is on the speaker board for Chiesi and Abbvie. The remaining authors have nothing to disclose.

Funding Information:
S.J. Schwarzenberg is a consultant for Abbvie, Mirium, Nestle, and UpToDate and has grant funding from the Cystic Fibrosis Foundation, the National Institutes of Health, and Gilead. T. Schindler is on the speaker board for Chiesi and Abbvie. The remaining authors have nothing to disclose.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Body composition
Cardiovascular risk
Cystic fibrosis transmembrane conductance regulator (CFTR)
Highly effective modulator therapy
Nutrient dense

PubMed: MeSH publication types

Journal Article
Review

Publisher link

10.1016/j.ccm.2022.06.012

Find It

Find It at U of M Libraries

Cite this

@article{aadefd14d41d4e1c976585c4c73484ef,

title = "Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era",

abstract = "Attainment and maintenance of good nutrition has been an important aspect of management in cystic fibrosis (CF) for decades. In the era of highly effective modulator therapy for CF, the quality of the nutrients we recommend is increasingly important. Our therapy must support our patients' health for many years beyond what we previously thought. Preventing cardiovascular disease, reducing hyperlipidemia, and optimizing lean body mass for active, longer lives now join the long-standing goal of promoting lung function through nutrition. This chapter summarizes recent developments in nutrition in people with CF, with an eye to the evolution of our practice.",

keywords = "Body composition, Cardiovascular risk, Cystic fibrosis transmembrane conductance regulator (CFTR), Highly effective modulator therapy, Nutrient dense",

author = "Alexandra Wilson and Kimberly Altman and Terri Schindler and Schwarzenberg, \{Sarah Jane\}",

note = "Funding Information: S.J. Schwarzenberg is a consultant for Abbvie, Mirium, Nestle, and UpToDate and has grant funding from the Cystic Fibrosis Foundation , the National Institutes of Health , and Gilead . T. Schindler is on the speaker board for Chiesi and Abbvie. The remaining authors have nothing to disclose. Funding Information: S.J. Schwarzenberg is a consultant for Abbvie, Mirium, Nestle, and UpToDate and has grant funding from the Cystic Fibrosis Foundation, the National Institutes of Health, and Gilead. T. Schindler is on the speaker board for Chiesi and Abbvie. The remaining authors have nothing to disclose.",

year = "2022",

month = dec,

doi = "10.1016/j.ccm.2022.06.012",

language = "English (US)",

volume = "43",

pages = "727--742",

journal = "Clinics in Chest Medicine",

issn = "0272-5231",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era

AU - Wilson, Alexandra

AU - Altman, Kimberly

AU - Schindler, Terri

AU - Schwarzenberg, Sarah Jane

N1 - Funding Information: S.J. Schwarzenberg is a consultant for Abbvie, Mirium, Nestle, and UpToDate and has grant funding from the Cystic Fibrosis Foundation , the National Institutes of Health , and Gilead . T. Schindler is on the speaker board for Chiesi and Abbvie. The remaining authors have nothing to disclose. Funding Information: S.J. Schwarzenberg is a consultant for Abbvie, Mirium, Nestle, and UpToDate and has grant funding from the Cystic Fibrosis Foundation, the National Institutes of Health, and Gilead. T. Schindler is on the speaker board for Chiesi and Abbvie. The remaining authors have nothing to disclose.

PY - 2022/12

Y1 - 2022/12

N2 - Attainment and maintenance of good nutrition has been an important aspect of management in cystic fibrosis (CF) for decades. In the era of highly effective modulator therapy for CF, the quality of the nutrients we recommend is increasingly important. Our therapy must support our patients' health for many years beyond what we previously thought. Preventing cardiovascular disease, reducing hyperlipidemia, and optimizing lean body mass for active, longer lives now join the long-standing goal of promoting lung function through nutrition. This chapter summarizes recent developments in nutrition in people with CF, with an eye to the evolution of our practice.

AB - Attainment and maintenance of good nutrition has been an important aspect of management in cystic fibrosis (CF) for decades. In the era of highly effective modulator therapy for CF, the quality of the nutrients we recommend is increasingly important. Our therapy must support our patients' health for many years beyond what we previously thought. Preventing cardiovascular disease, reducing hyperlipidemia, and optimizing lean body mass for active, longer lives now join the long-standing goal of promoting lung function through nutrition. This chapter summarizes recent developments in nutrition in people with CF, with an eye to the evolution of our practice.

KW - Body composition

KW - Cardiovascular risk

KW - Cystic fibrosis transmembrane conductance regulator (CFTR)

KW - Highly effective modulator therapy

KW - Nutrient dense

UR - https://www.scopus.com/pages/publications/85141313598

UR - https://www.scopus.com/pages/publications/85141313598#tab=citedBy

U2 - 10.1016/j.ccm.2022.06.012

DO - 10.1016/j.ccm.2022.06.012

M3 - Review article

C2 - 36344077

AN - SCOPUS:85141313598

SN - 0272-5231

VL - 43

SP - 727

EP - 742

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

IS - 4

ER -

Updates in Nutrition Management of Cystic Fibrosis in the Highly Effective Modulator Era

Abstract

Bibliographical note

UN SDGs

Keywords

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this